Download PDF
Thromb Haemost 2020; 120(09): 1323-1329
DOI: 10.1055/s-0040-1713889
Stroke, Systemic or Venous Thromboembolism

Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review

Tim A. C. de Vries 
1   Population Health Research Institute, Hamilton, Ontario, Canada
2   Department of Cardiology, Rijnstate Hospital, Arnhem, Gelderland, The Netherlands
3   Department of Cardiology, Amsterdam University Medical Centers/University of Amsterdam, Amsterdam, North Holland, The Netherlands
,
Jack Hirsh
4   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
5   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Ke Xu
1   Population Health Research Institute, Hamilton, Ontario, Canada
6   Department of Cardiology, Shanghai Jiao Tong University, Shanghai, China
,
Imaad Mallick
1   Population Health Research Institute, Hamilton, Ontario, Canada
,
Vinai C. Bhagirath
4   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
5   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
John W. Eikelboom
1   Population Health Research Institute, Hamilton, Ontario, Canada
4   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
5   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Jeffrey S. Ginsberg
4   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
5   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Paul C. Kruger
1   Population Health Research Institute, Hamilton, Ontario, Canada
7   Department of Haematology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
,
Noel C. Chan
1   Population Health Research Institute, Hamilton, Ontario, Canada
4   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
5   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background Recent reports suggest an important contribution from frequent off-label use of apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in observational studies (OSs) relative to in randomized controlled trials (RCTs), and consequently, advocate against such use in all patients.

Objectives To examine factors contributing to the higher thromboembolic event rates, we estimated the prevalence of off-label use in contemporary practice, and compared patient characteristics and rates of stroke/systemic embolism, major bleeding, and mortality by apixaban dose and by study design in a systematic review and meta-analysis.

Results and Discussion We identified 18 OSs and 2 RCTs that included 155,228 and 11,928 patients, respectively. Patients in OSs more often received apixaban 2.5 mg twice daily (31.3% vs. 5.1%), were older (mean age 73.8 vs. 69.8 years), and had higher CHA2DS2-VASc scores (mean 3.6 vs. 2.9) versus those in RCTs. We observed a consistent pattern of higher rates of thromboembolic events, bleeding, and mortality in patients treated with 2.5 versus 5 mg twice daily apixaban in both OSs and RCTs.

Conclusion The higher risk profiles of patients in OSs versus RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice.

Keywords

anticoagulants - death - hemorrhage - off-label - thromboembolism

Authors' Contributions

T.A.C.V., J.H., V.C.B., J.W.E., J.S.G., P.C.K., and N.C.C. have contributed to the concept and design of the study. T.A.C.V., J.H., and N.C.C. developed the study protocol, designed, and coordinated the study. T.A.C.V., K.X., and N.C.C. developed the search strategy. T.A.C.V. and K.X. tailored the search strategy, performed the literature searches, and extracted the data. T.A.C.V. and K.X. performed the quality assessments, and any disagreement was resolved by N.C.C.. T.A.C.V., J.H., V.C.B., J.S.G., J.W.E., and N.C.C. developed the initial analysis plan. T.A.C.V. and I.M. performed the analysis. T.A.C.V., J.H., and N.C.C. wrote the initial draft and subsequent iterations. All the other authors reviewed the drafts, provided critical comments, and revised the initial draft to produce the final manuscript.


Supplementary Material



Publication History

Received: 09 September 2019

Accepted: 17 May 2020

Article published online:
15 July 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Connolly SJ, Eikelboom J, Joyner C. , et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
    CrossrefPubMedGoogle Scholar
  • 2 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 3 Adeboyeje G, Sylwestrzak G, Barron JJ. , et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2017; 23 (09) 968-978
    Google Scholar
  • 4 Chan YH, Lee HF, See LC. , et al. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest 2019; 156 (03) 529-543
    CrossrefPubMedGoogle Scholar
  • 5 Chan YH, See LC, Tu HT. , et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc 2018; 7 (08) e008150
    CrossrefPubMedGoogle Scholar
  • 6 Cho MS, Yun JE, Park JJ. , et al. Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in Asian patients with atrial fibrillation. Stroke 2018 (PMID: . Strokeaha118023093)
    PubMedGoogle Scholar
  • 7 Ellis MH, Avnery P, Derazne E. , et al. Bleeding in patients with atrial fibrillation treated with different doses of direct oral anticoagulants and vitamin k antagonists: a population-based study. Blood 2016; 128 (22) 2617
    CrossrefPubMedGoogle Scholar
  • 8 Halvorsen S, Ghanima W, Fride Tvete I. , et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017; 3 (01) 28-36
    CrossrefPubMedGoogle Scholar
  • 9 Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non-vitamin k oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost 2018; 118 (03) 526-538
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M. Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a regulatory postmarketing surveillance, the STANDARD study. J Arrhythm 2019; 35 (03) 506-514
    CrossrefPubMedGoogle Scholar
  • 11 Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M. Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a sub-analysis of the STANDARD study. J Cardiol 2020; 75 (02) 208-215
    CrossrefPubMedGoogle Scholar
  • 12 Kjerpeseth LJ, Selmer R, Ariansen I, Karlstad Ø, Ellekjær H, Skovlund E. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: a nationwide pharmacoepidemiological study. PLoS One 2019; 14 (08) e0221500
    CrossrefPubMedGoogle Scholar
  • 13 Lamberts M, Staerk L, Olesen JB. , et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Heart Assoc 2017; 6 (02) e004517
    CrossrefPubMedGoogle Scholar
  • 14 Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016; 353: i3189
    CrossrefPubMedGoogle Scholar
  • 15 Lee SR, Choi EK, Kwon S. , et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke 2019; 50 (08) 2245-2249
    CrossrefPubMedGoogle Scholar
  • 16 Lip GYH, Keshishian A, Li X. , et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke 2018; 49 (12) 2933-2944
    CrossrefPubMedGoogle Scholar
  • 17 Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol 2019; 85 (02) 422-431
    CrossrefPubMedGoogle Scholar
  • 18 Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510
    CrossrefPubMedGoogle Scholar
  • 19 Ramagopalan SV, Sicras-Mainar A, Polanco-Sanchez C, Carroll R, de Bobadilla JF. Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study. J Comp Eff Res 2019; 8 (14) 1201-1212
    CrossrefPubMedGoogle Scholar
  • 20 Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018; 362: k2505
    CrossrefPubMedGoogle Scholar
  • 21 Rose M, Beasley BN. Center for drug evaluation and research application number: 202155orig1s000 medical review(s). Published 2012. Updated December 17, 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000MedR.pdf . Accessed December 18, 2019
    PubMedGoogle Scholar
  • 22 Rivera-Caravaca JM, Esteve-Pastor MA, Marín F. , et al. A propensity score matched comparison of clinical outcomes in atrial fibrillation patients taking vitamin k antagonists: comparing the “real-world” vs clinical trials. Mayo Clin Proc 2018; 93 (08) 1065-1073
    CrossrefPubMedGoogle Scholar
  • 23 Santos J, Antonio N, Rocha M, Fortuna A. Impact of direct oral anticoagulants off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol 2020; 86 (03) 533-547
    CrossrefPubMedGoogle Scholar
  • 24 Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ. Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med 2016; 129 (11) 1198-1204
    CrossrefPubMedGoogle Scholar
  • 25 Başaran Ö, Dogan V, Beton O. , et al; Collaborators. Suboptimal use of non-vitamin K antagonist oral anticoagulants: results from the RAMSES study. Medicine (Baltimore) 2016; 95 (35) e4672
    CrossrefPubMedGoogle Scholar
  • 26 Gibson CM, Smith CB, Davis S, Scalese MJ. Assessment of apixaban prescribing patterns for nonvalvular atrial fibrillation in hospitalized patients. Ann Pharmacother 2018; 52 (01) 54-59
    CrossrefPubMedGoogle Scholar
  • 27 Okumura Y, Yokoyama K, Matsumoto N. , et al; The Sakura Af Registry Investigators. Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry. J Arrhythm 2017; 33 (04) 289-296
    CrossrefPubMedGoogle Scholar
  • 28 Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother 2018; 52 (11) 1078-1084
    CrossrefPubMedGoogle Scholar
  • 29 Steinberg BA, Shrader P, Thomas L. , et al; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the Orbit-AF II Registry. J Am Coll Cardiol 2016; 68 (24) 2597-2604
    CrossrefPubMedGoogle Scholar
  • 30 Umei M, Kishi M, Sato T. , et al. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm 2017; 33 (05) 475-482
    CrossrefPubMedGoogle Scholar
  • 31 Yamashita Y, Uozumi R, Hamatani Y. , et al. Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients- Fushimi AF Registry. Circ J 2017; 81 (09) 1278-1285
    CrossrefPubMedGoogle Scholar
  • 32 Arbel R, Sergienko R, Hammerman A. , et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. Am J Med 2019; 132 (07) 847-855.e3
    CrossrefPubMedGoogle Scholar
  • 33 Steinberg BA, Shrader P, Pieper K. , et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) II Investigators. Frequency and outcomes of reduced dose non-vitamin k antagonist anticoagulants: results from Orbit-AF II (the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 2018; 7 (04) e007633
    CrossrefPubMedGoogle Scholar
  • 34 Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin k antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017; 69 (23) 2779-2790
    CrossrefPubMedGoogle Scholar
  • 35 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 36 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedGoogle Scholar
  • 37 Spencer FA, Iorio A, You J. , et al. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ 2012; 345: e7401-e7401
    CrossrefPubMedGoogle Scholar
  • 38 Iorio A, Spencer FA, Falavigna M. , et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015; 350: h870
    CrossrefPubMedGoogle Scholar
  • 39 Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Routledge; 1988. DOI: 10.4324/9780203771587
    CrossrefGoogle Scholar
  • 40 Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: Wiley; 2009
    CrossrefGoogle Scholar
  • 41 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (03) 177-188
    CrossrefPubMedGoogle Scholar
  • 42 Freeman M, Tukey J. Transformations related to the angular and the square root. Ann Math Stat 1950; 21: 607-611
    CrossrefPubMedGoogle Scholar
  • 43 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135
    CrossrefPubMedGoogle Scholar
  • 44 Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991
    Google Scholar
  • 45 Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317 (7168): 1309-1312
    CrossrefPubMedGoogle Scholar
  • 46 Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998; 147 (08) 783-790
    CrossrefPubMedGoogle Scholar
  • 47 Lopes RD, Al-Khatib SM, Wallentin L. , et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012; 380 (9855): 1749-1758
    CrossrefPubMedGoogle Scholar
  • 48 Bhagirath VC, Eikelboom JW, Hirsh J. , et al. Apixaban-calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open 2017; 1 (02) e139-e145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Paikin JS, Hirsh J, Chan NC, Ginsberg JS, Weitz JI, Eikelboom JW. Timing the first postoperative dose of anticoagulants: lessons learned from clinical trials. Chest 2015; 148 (03) 587-595
    CrossrefPubMedGoogle Scholar